Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 148-155, April 2002

111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial1

  • Irene Virgolini

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • Corresponding Author InformationAddress reprint requests to Irene Virgolini, MD, Institute of Nuclear Medicine, Lainz Hospital, City of Vienna, Wolkersbergenstrasse 1, A-1130 Vienna, Austria
    • ,
  • Keith Britton

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • John Buscombe

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • Roy Moncayo

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • Giovanni Paganelli

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy
    • Ospedale Bufalini, Cesena, Italy
    • ,
  • Pietro Riva

      Affiliations

    • Department of Nuclear Medicine, University of Vienna, Vienna, Austria
    • Department of Nuclear Medicine, University of Innsbruck Innsbruck, Austria
    • Royal Trust Hospital and Royal Free Hospital, London, UK
    • Istituto Europeo di Oncologia, Milan, Italy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

1 Supported in part by the Austrian National Bank, Anniversary Foundation Projects 7556 and 8320, as well as by an Anniversary Foundation of the Mayor of the City of Vienna.

PII: S0001-2998(02)80033-2

doi:10.1053/snuc.2002.31565

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 148-155, April 2002

Article Tools